BIOMAT Database Logo BIOMAT Database Logo

Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial. 2001

E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Medical Oncology Dept., Hospital Universitario Reina Sofía, Avenida Menéndez Pidal, s/n 14004, Córdoba, Spain. earanda@ene.es

The objective of this study was to evaluate the activity and toxicity of tegafur and uracil (UFT; 1:4 molar ratio) plus leucovorin (LV) in patients with advanced colorectal cancer. One hundred forty-one patients were entered into the study. The treatment schedule consisted of UFT 300 mg/m2/day (in three divided doses) plus oral LV 150 mg/day (50 mg t.i.d.) over 28 days. The treatment cycle was repeated every 5 weeks until progression or unacceptable toxicity was observed. The treatment was interrupted if grade 3/4 toxicity appeared and was resumed at the same dosage on recovery. One hundred thirty-six patients were evaluable for response and 141 were evaluable for toxicity. The response rate was 19.9% (95% confidence interval: 12%-28%). The total number of patients without progression (objective response + stable disease) was 76 (55.9%). The median time to progression was 5.6 months, and the overall survival was 11.6 months. The toxicity profile was low, with 11% of patients experiencing grade 3/4 nausea and vomiting, while 17% had grade 3/4 diarrhea. Oral administration of UFT modulated with LV is a comfortable regimen of chemotherapy for patients with advanced colorectal cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma.
January 1998, Investigational new drugs,
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
January 1999, Investigational new drugs,
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
February 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial).
August 2021, International journal of colorectal disease,
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study.
December 1995, European journal of cancer (Oxford, England : 1990),
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas.
July 2003, Japanese journal of clinical oncology,
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
[Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer].
November 2005, Gan to kagaku ryoho. Cancer & chemotherapy,
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
August 2012, Journal of chemotherapy (Florence, Italy),
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
March 2013, Oncology reports,
E Aranda, and A Antón-Torres, and J Sastre, and M Navarro, and F Rivera, and A Carrato, and J J Bretón, and J Aparicio, and C Fernández-Martos, and E Díaz-Rubio, and
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
September 1998, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!